This article was originally published on PharmaTimes http://www.pharmatimes.com/news/keytruda_prolongs_recurrence-free_survival_in_melanoma,_study_shows_1231954

MSD and the European Organisation for Research and Treatment of Cancer (EORTC) have released new data showing that the anti-PD-1 therapy Keytruda significantly prolonged recurrence-free survival (RFS) in patients with high-risk stage III melanoma.

Related Posts